Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 16:01 ET | Source: Alvotech

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

REYKJAVIK, Iceland, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
November 04, 2025 16:01 ET | Source: Alvotech

Alvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekstri félagsins þann 13. nóvember nk.

Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrstu níu mánaða ársins 2025 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 12. nóvember nk. Fundur til kynningar á uppgjörinu verður...
November 04, 2025 16:01 ET | Source: Alvotech

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

REYKJAVIK, ICELAND (November 4, 2025) – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today...
November 02, 2025 17:12 ET | Source: Alvotech

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
November 02, 2025 17:10 ET | Source: Alvotech

Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT05 í Bandaríkjunum

Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að fyrirtækið hafi móttekið svarbréf frá Lyfja- og matvælaeftirliti Bandaríkjanna (FDA) við umsókn um markaðsleyfi fyrir AVT05, í áfylltri sprautu og...
November 02, 2025 17:10 ET | Source: Alvotech

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

REYKJAVIK, ICELAND (November 2, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced...
October 22, 2025 05:00 ET | Source: Alvotech

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

REYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
October 06, 2025 04:40 ET | Source: Alvotech

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty,...
September 22, 2025 06:15 ET | Source: Alvotech

Evrópska lyfjastofnunin mælir með útgáfu markaðsleyfis fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva

Alvotech (NASDAQ: ALVO) tilkynnti í dag að mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hafi mælt með því að veita markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin...
September 22, 2025 06:15 ET | Source: Alvotech

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...